---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035426"
form_type: "8-K"
ticker: "BLGO"
cik: "0000880242"
company_name: "BIOLARGO, INC."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-30T00:08:11.847065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows

## Summary
- Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.
- Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).
- Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.
- CEO says tenth consecutive year of record revenue; expects 2025 to be another record.
- Investing in production for national rollout of Clyra Medical Technologies products.

## SEC filing metadata
- accession: 0001437749-24-035426
- form_type: 8-K
- ticker: BLGO
- cik: 0000880242
- company_name: BIOLARGO, INC.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/0001437749-24-035426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/blgo20241114_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035426
- JSON: https://secwatch.observer/filing/0001437749-24-035426.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.